Press Release Details

G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021

October 20, 2021 at 8:00 AM EDT

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET.

The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. The live and archived webcast will be available on the Events & Presentations page of

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711  

Primary Logo

Source: G1 Therapeutics